Head to Head Analysis: Interpace Biosciences (OTCMKTS:IDXG) vs. Ethema Health (OTCMKTS:GRST)

Institutional & Insider Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. 0.9% of Interpace Biosciences shares are held by company insiders. Comparatively, 55.7% of Ethema Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Interpace Biosciences and Ethema Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	65.25%	219.07%	105.05%
Ethema Health	-11.61%	N/A	-7.48%

Volatility and Risk

Interpace Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Ethema Health has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

Valuation & Earnings

This table compares Interpace Biosciences and Ethema Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.18	$24.58 million	($0.05)	-32.20
Ethema Health	$18.76 million	0.00	-$2.18 million	N/A	N/A

Interpace Biosciences has higher revenue and earnings than Ethema Health.

Summary

Interpace Biosciences beats Ethema Health on 6 of the 8 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Ethema Health

Ethema Health Corporation operates behavioral healthcare space specifically in the treatment of substance use disorders. It offers rehabilitation services. The company was formerly known as GreeneStone Healthcare Corporation and changed its name to Ethema Health Corporation in April 2017. Ethema Health Corporation is based in West Palm Beach, Florida.